v3.21.1
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Net sales $ 243,552 $ 194,680 $ 672,004 $ 562,857
Cost of sales 75,278 64,617 215,098 192,977
Gross margin 168,274 130,063 456,906 369,880
Operating expenses:        
Selling, general and administrative 82,596 66,318 238,310 203,358
Research and development 17,052 15,954 49,882 48,413
Total operating expenses 99,648 82,272 288,192 251,771
Operating income 68,626 47,791 168,714 118,109
Other (expense) income (23,272) (970) (27,652) 96,843
Earnings before income taxes 45,354 46,821 141,062 214,952
Income taxes (48) 10,389 16,121 44,501
Net earnings, including noncontrolling interest 45,402 36,432 124,941 170,451
Net earnings (loss) attributable to noncontrolling interest (380) 0 (509) 0
Net earnings attributable to Bio-Techne 45,782 36,432 125,450 170,451
Other comprehensive (loss) income:        
Foreign currency translation adjustments (1,142) (19,403) 27,700 (15,138)
Derivative instruments - cash flow hedges 1,288 (5,702) 5,490 (4,798)
Other comprehensive income (loss) 146 (25,105) 33,190 (19,936)
Other comprehensive income (loss) attributable to noncontrolling interest (69) 0 14 0
Other comprehensive income attributable to Bio-Techne 215 (25,105) 33,176 (19,936)
Comprehensive income attributable to Bio-Techne $ 45,997 $ 11,327 $ 158,626 $ 150,515
Earnings per share attributable to Bio-Techne:        
Basic (in dollars per share) $ 1.18 $ 0.95 $ 3.24 $ 4.46
Diluted (in dollars per share) $ 1.12 $ 0.92 $ 3.11 $ 4.33
Weighted average common shares outstanding:        
Basic (in shares) 38,856 38,303 38,693 38,167
Diluted (in shares) 40,676 39,435 40,305 39,354

Source